AARD - NASDAQ
Aardvark Therapeutics, Inc. Common Stock
$4.01
+5.2%Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
At a Glance
Live Snapshotaard
Cost of Revenue
Last Annual Value
36.00K
3-Year CAGR
%
5-Year CAGR
%
10-Year CAGR
%
Aardvark Therapeutics, Inc. Common Stock Competitors Analysis of Cost of Revenue
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Aardvark Therapeutics, Inc. Common Stock NASDAQ:AARD | 36.00K | N/A | N/A | N/A | |
 Avalo Therapeutics, Inc. NASDAQ:AVTX | 344.00K | -35.5% | -25.4% | -27.2% | |
 Aldeyra Therapeutics, Inc. NASDAQ:ALDX | 0.00 | N/A | N/A | N/A | |
 Annexon, Inc. NASDAQ:ANNX | 3.69M | N/A | N/A | N/A | |
 Candel Therapeutics, Inc. NASDAQ:CADL | 845.00K | -67.2% | -43.4% | N/A | |
323.00K | N/A | N/A | N/A | ||
 Editas Medicine, Inc. NASDAQ:EDIT | 0.00 | N/A | N/A | N/A | |
 Galectin Therapeutics Inc. NASDAQ:GALT | 0.00 | N/A | N/A | N/A | |
 Assembly Biosciences, Inc. NASDAQ:ASMB | 129.00K | -86.2% | N/A | 4.9% | |
 Enanta Pharmaceuticals, Inc. NASDAQ:ENTA | 4.59M | N/A | N/A | N/A | |
 Nautilus Biotechnology, Inc. NASDAQ:NAUT | 6.46M | 4.3% | 17.9% | N/A |
Aardvark Therapeutics, Inc. Common Stock Fair Value Envelope
Related Guides
Continue your AARD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.